Bioasis Appoints Names Rathjen as President and Chief Executive Officer
12 March 2019 - - US-based biopharmaceutical company Bioasis Technologies Inc's (OTCQB: BIOAF) (TSX Venture: BTI) board of directors has appointed Dr. Deborah A. Rathjen as president and chief executive officer, the company said.

Dr. Rathjen, who is a member of the board of directors and has served as executive chair since December 10, 2018, replaces Dr. Mark Day, who has left the company, effective immediately.

The board would like to thank Dr. Mark Day for his contributions to the company over the past few years and wish him well in his future endeavours.

Bioasis also said it has recently granted stock options to acquire a total of 1.616m common shares at exercise prices ranging from USD 0.445 – USD 0.55 per share to executives of the company, with the exception of Dr. Rathjen. 95,000 of these options vest over a period of one year and the balance vest over a period of five years.

All of the options have a five year term and are governed by the terms of the company's stock option plan.

Bioasis Technologies is a biopharmaceutical company developing the xB3 TM platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need.

The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. Bioasis' internal pipeline programs are focused on treatments for orphan indications, including certain brain cancers, and rare diseases, including Gaucher's Disease Type II.

The company maintains headquarters in Guilford, Connecticut.